来源：视频滚动新闻 美股周五早盘，消费者健康企业Kenvue(KVUE)下跌0.8%，此前该公司宣称，美国卫生部长小罗伯特·肯 尼迪(RFK Jr.)称证据"不足以"证明泰诺(Tylenol)导致自闭症。Kenvue是泰诺的生产商，该公司重申药品 安全性，并建议使用者遵循医嘱。 ...

Kenvue Inc. (NYSE:KVUE) is one of the best up and coming stocks to buy right now. On October 27, Jefferies analyst Keith Devas lowered the firm’s price target on Kenvue to $23 from $25 and maintained a Buy rating on the shares, as the current macroeconomic challenges are impacting consumer health stocks more than the consumer staples sector. Resultantly, Jefferies lowered its price targets and earnings estimates for the entire consumer health coverage ahead of Q3 2025 reports. Earlier on October 24, Deuts ...

On 22 July 2025, my first analysis about Kenvue ( KVUE ), the former consumer health division of Johnson & Johnson ( JNJ ), was published. I rated the stock a "sell" due to a strong overvaluation as well as expectationsAlways on the hunt for undervalued, promising stocks with a focus on risk and reward. Limited risks and decent to high upside by knowing what one's owning. I strongly believe that the best investment ideas are often the simplest. If contrarian, the better.Analyst’s Disclosure:I/we have no sto ...

Kenvue, Inc. ( KVUE ) is an American consumer health company that spun off from Johnson & Johnson ( JNJ ) in May 2023 and now operates as an independent brand. The company offers personalDear Reader,I am a Senior Derivatives Expert with over 10 years of experience in the field of Asset Management, specializing in equity analysis and research, macroeconomics, and risk-managed portfolio construction. My professional background covers both institutional and private client asset management, where I have advised ...

Kenvue Inc. (NYSE:KVUE) is one of the most buzzing stocks to buy with huge upside potential. On October 24, Deutsche Bank lowered the firm’s price target on Kenvue to $18 from $20 and kept a Hold rating on the shares. Earlier on October 10, JPMorgan also lowered the firm’s price target on Kenvue to $21 from $24 and kept an Overweight rating on the shares as part of a Q3 2025 preview for the household, personal care, and beauty group. Deutsche Bank Lowers Kenvue (KVUE) PT to $18, Keeps a Hold Rating JPMo ...

公司评级与股价表现 - Johnson Rice将Kenvue Inc (NYSE: KVUE)的评级更新为中性 维持持有建议 当前股价为14.59美元 [1] - 公司当前股价为14.64美元 较前一交易日下跌约2.95% 当日下跌0.45美元 交易区间在14.56美元至14.93美元之间 [4] - 公司过去一年股价波动显著 最高达25.17美元 最低为14.05美元 [4] 公司财务与市场数据 - 公司市值约为280.9亿美元 当日交易量为752万股 [5] - 当前股价为14.64美元 较前一交易日下跌约2.95% [4][6] 重大法律挑战 - 德克萨斯州总检察长Ken Paxton对Kenvue及强生公司提起诉讼 指控其隐瞒泰诺(Tylenol)可能与自闭症和注意力缺陷多动障碍(ADHD)存在潜在关联的信息 [2] - 诉讼特别指控公司通过欺骗性营销手段 误导孕妇关于泰诺在怀孕期间的安全性 声称其与自闭症风险相关 [3] - 该法律诉讼对公司的广告策略和消费者信任构成挑战 可能影响公司声誉和财务状况 [2][3]

CHARLOTTE, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced the closing of its previously announced best efforts public offering (the “Offering”) of (i) 2,722,642 Class A ordinary shares, par value $0.0015 per share, of the Company (the “Ordinary Shares,” the Ordinary Shares being sold in the Offering, the “Shares”), (ii) warrants of the Company to purchase up to 2,722,642 Ordinary Shares (the “C ...

UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts. “We are entering a transformative phase for ProPhase,” said Ted Karkus, CEO and Chairman of ProPhase Labs. “With the imminent commercialization of our BE-Smart™ esophageal cancer diagnostic, continued expansion of our Nebul ...

公司股价与市场表现 - 当前股价为15美元，微跌0.60%（下跌0.09美元）[3] - 公司市值约为287.9亿美元，在市场中占据重要地位[4] - 股票交易量为1242万股，显示投资者兴趣活跃[4] 分析师观点与价格目标 - Jefferies为公司设定了23美元的目标价，暗示较当前股价有53.33%的上涨潜力[1][5] - 这一乐观展望反映了对公司未来表现的信心[1] 财务业绩发布安排 - 公司计划于2025年11月6日美股市场开盘前发布2025年第三季度财务业绩[2][5] - 业绩发布后将举行电话会议和网络直播，时间为美国东部时间上午8:30[2] 股价历史波动范围 - 当日股价波动区间为14.99美元至15.28美元[3] - 过去52周，股价最高达到25.17美元，最低触及14.05美元，显示存在一定波动性[3]

CHARLOTTE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced the successful pricing of a best efforts public offering (the “Offering”) of (i) 2,992,596 Class A ordinary shares, par value $0.0015 per share, of the Company (the “Ordinary Shares,” the Ordinary Shares being sold in the Offering, the “Shares”) (or pre-funded warrants of the Company to purchase Ordinary Shares (the “Pre-funded Warrants” ...